Polyrizon Ltd (PLRZ) 시세

All the data is from 5-30-25
No new data
Nobody knows
Guys showing screenshots of data from half a month ago lol.

Looks like shorts have covered and with very little upside movement. Significant Failures to Deliver
No . Still hope to see some good news but i think that's a long shot. Best of luck

Need to see the new short interest It's 6/17.....should have been out by now. MM must have oversold short a new record lol

Motley check Premarket Getting frisky?

For 5/14 238k ftdhttps://chartexchange.com/symbol/nasdaq-plrz/failure-to-deliver/

Borrow rate still 189%

Significant Failures to Deliver
Yes
https://www.otcmarkets.com/stock/PLRZ/security

Reminds me of DRYS Dry ships out a Greece Butt load of RS and then it went from like .03 to 92.5 lol

SI still 1,000% per fintel. Thats 50 million naked borrowed shares. Only a matter of time before another tute sees the easy money grab here.

Borrow rate 188% now

Borrow rate is now 170%

My thinking remains. Why stay if one believes it will be delisted?

If my memory serves me correct. Seems I remember reading in one of the recent filings they were going to keep the Authorized Shares at 2 Billion. I’ll have to look again but I’m pretty sure they stated such in a filing pertaining to the reverse split announcement.

We've been here for a while buddy. Your late to the party. Stocks change like the wind based on new info. And they've already been warned but it looked a little promising after the reverse split. But now it appears they are just going to dillute the piss out of this and not even care and just play games and steal as much money as possible before they exit the NASDAQ with a big wad of cash in managements pockets while we are left with nothing. Happens all the time. Penny Stocks are mostly just legalized theft with no actual plans to ever really have a legit business. They just come up with a catchy or trendy idea that sounds good and are granted a ticker. All you need is a ticker to sell shares and your rich and you can do it over and over again the more you learn how to navigate the system and the more crooks you get to know.

got cha back cheers POLYRIZON

So if you believe "they" could be delisted what are you doing still in it?

I'm getting out Monday I think. They keep closing below $1. This could get delisted at any second.

Nerve wracking for sure

Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial
This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.

Ya I'm staying with that borrow rate. Sitting on my hands lol

This price action suggests games being played to entice us to sell before next weeks rally. Just my opinion.

Needs volume. Some news would send this flying.

Borrow rate is 16,800% nowShould be squeezing if time is money lol

IF those numbers are correct buckle up buttercup.. PLRZ

When you put it that way.....damn smart.

If this company is serious about regaining compliance, there will be no more dillution for at least 6 months after appeal hearing. The new nasdaq dollar bid price compliance rules isnt as simple as maintaining a dollar closing price for ten days. They cant R/S again according to new rules to achieve compliance. The OS will stay at current levels for another 6 months as shorts get eaten alive by 33,000 percent borrow fees...............well played PLRZ!

Hell yes Probably talking with the company now about how they get out of this dilemma.I say let them burn;)

According to fintel 1,000% short interest. That equates to approximately 50 million borrowed shares. How are they going to cover when there is only 5 million shares outstanding? This could be bigger than GameStop.

No more halts just let it fly. Float is locked 10x over, no shares available for short interest 

A lot of action this morning

PLPZ...................................................................................p/m

Ya I just hold right now CTB is ridiculous PPs should be a lot higher

Looks good in the AM! Let's rock!

Fintel finally updated the short interest and ctb..........Short interest is now over 1,000% of float and cost to borrow is 33,646.94% Guessing tons of nakeds held through R/S counting on delisting and or BK. Not gonna happen with the new OS and massive cash on hand. Here is fintel short interest link
https://fintel.io/ss/us/plrz

A little news story will send it

Best stock of the day for me. Flipped once. Bought back at 79. Just waiting to see what tomorrow brings

Thanks motley5m shares at $1 seems undervalued 

5,328,332 is the number from last 6k filing regarding the R/S effective yesterday here is the link. https://www.sec.gov/Archives/edgar/data/1893645/000121390025046620/ea0243080-6k_polyrizon.htm
Guessing they have between 40-50 mil on hand after the recent dilution.

Around 5 mil......dilution is over for now til they regain compliance. They could buy all OS at these prices and still have multi tens of millions cash left. Fintel ctb is 134% atm but expect it to jump up significantly.

What you think the OS is?

Cash value puts this north of 8 bucks.......just sayin.

Your welcome. Sometimes all it takes is bringing bad behavior and bad business practices to the attention of the right entities to get a company to see the error of their ways.....mission accomplished I guess

Uh I don't think there are shares to borrow showing 33,000 % lol

lol nice 

Just sold at .99 for a nice 30% flip. Might keep going. Who knows

I'd like to know what the real OS is now?Can't be 5m

I told y'all they had 10 days to be under .10 no matter what. There are no exceptions for that without a plan

I was very fortunate that I didn't completely lose my arse here. This is another MULN. I had $300 worth when it tanked from .35 to .03 in 5 minutes. But other than that loss I came out on top with my flips and just stayed away the last couple of days even this gh it was very enticing at those low prices. Just complete luck I didn't buy more share the last couple of days.

Correction: Not the SEC but the NASDAQ Listing Qualifications Staff




Specifically, as set forth in the letter, Nasdaq’s staff determined that the Company’s issuance of securities pursuant to the securities purchase agreement dated March 31, 2025, particularly the Series A warrants exercisable on an alternate cashless basis as described in the Company’s prior SEC filings, raises public interest concerns because the issuance resulted in substantial dilution for its shareholders.





familyof5 Re: familyof5
Saturday, May 24, 2025 2:16:49 PM

Looks like PLRZ caught the eye of the SEC https://www.sec.gov/Archives/edgar/data/1893645/000121390025047370/ea0243291-6k_polyrizon.htm



EX-99.1 2 ea024329101ex99-1_polyrizon.htm PRESS RELEASE TITLED: "POLYRIZON ANNOUNCES RECEIPT OF NASDAQ DELISTING NOTICE"

Exhibit 99.1


Polyrizon Announces Receipt of Nasdaq Delisting Notice



Raanana, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), stating that based on its review of the Company’s public filings with the Securities and Exchange Commission (the “SEC”), its staff has determined to delist the Company’s securities pursuant to its discretionary authority under Listing Rule 5101. The receipt of the Nasdaq notification letter does not result in the immediate delisting of the Company’s ordinary shares and has no current immediate effect on the listing or trading of the Company’s ordinary shares on the Nasdaq Capital Market, under symbol “PLRZ.”



Specifically, as set forth in the letter, Nasdaq’s staff determined that the Company’s issuance of securities pursuant to the securities purchase agreement dated March 31, 2025, particularly the Series A warrants exercisable on an alternate cashless basis as described in the Company’s prior SEC filings, raises public interest concerns because the issuance resulted in substantial dilution for its shareholders.



Accordingly, and as described in the notification letter, unless the Company timely requests a hearing before a Hearings Panel (the “Panel”), the Company’s securities would be subject to suspension/delisting. Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing.



About Polyrizon



Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.



Forward Looking Statements



This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the Company’s ability to continue to remain listed on Nasdaq and the Company’s ability to successfully appeal the Nasdaq staff’s delisting determination. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC.. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.



Contacts:



Michal Efraty
Investor Relations
IR@polyrizon-biotech.com